공지
- [ 2024-11-20 ] 한국의료윤리학회 - 추계합동학술대회 개최 안내(11/23(토))
- [ 2024-11-18 ] 국가생명윤리심의위원회 홈페이지 만족도 조사 안내
- [ 2024-11-15 ] 국가생명윤리정책원 생명윤리센터 채널의 '생명윤리법 제정 00주...
- [ 2024-11-12 ] 2024년 하반기 배아생성의료기관 종사자 교육 안내
- [ 2024-10-30 ] 개인정보 침해를 당했을 시 구제 방법 안내
관련 논문
*정책원 미소장 자료이며 관련 논문 소개 게시판입니다. 게시물 관련링크를 눌러 소속기관에서 열람가능한지 확인해주시기 바랍니다.
lib@nibp.kr
글 수 4,668
장기이식 거부반응과 자가면역질환 치료제로서의 CAR Treg 세포치료제의 가능성: Treg 세포치료제 임상시험 현황과 CAR T 세포치료제 허가 정보를 바탕으로 / 강고은 외
19 장기 조직 이식 조회 수 285 추천 수 0 2018.07.25 10:25:34| 발행년 : | 2017 |
|---|---|
| 구분 : | 국내학술지 |
| 학술지명 : | 大韓移植學會誌 |
| 관련링크 : | http://www.riss.kr/link?id=A105034313 |
장기이식 거부반응과 자가면역질환 치료제로서의 CAR Treg 세포치료제의 가능성: Treg 세포치료제 임상시험 현황과 CAR T 세포치료제 허가 정보를 바탕으로
= Current Perspectives on Emerging CAR-Treg Cell Therapy: Based on Treg Cell Therapy in Clinical Trials and the Recent Approval of CAR-T Cell Therapy
- 저자[authors] 강고은 ( Koeun Kang ), 정준호 ( Junho Chung ), 양재석 ( Jaeseok Yang ), 김효리 ( Hyori Kim )
- 학술지명[periodical name] 大韓移植學會誌
- 권호사항[Volume/Issue] Vol.31No.4[2017]
- 발행처[publisher] 대한이식학회
- 자료유형[Document Type] 학술저널
- 수록면[Pagination] 157-169
- 언어[language] Korean
- 발행년[Publication Year] 2017
- 주제어[descriptor] Transplantation, Rejection, Autoimmune disease, Regulatory T cells, Chimeric antigen receptor, 장기이식, 거부반응, 자가면역질환, 조절 T 세포, 키메라 항원 수용체
초록[abstracts]
[Regulatory T cells (Treg) naturally rein in immune attacks, and they can inhibit rejection of transplanted organs and even reverse the progression of autoimmune diseases in mice. The initial safety trials of Treg against graft-versus-host disease (GVHD) provided evidence that the adoptive transfer of Treg is safe and capable of limiting disease progression. Supported by such evidence, numerous clinical trials have been actively investigating the efficacy of Treg targeting autoimmune diseases, type I diabetes, and organ transplant rejection, including kidney and liver. The limited quantity of Treg cells harvested from peripheral blood and subsequent in vitro culture have posed a great challenge to large-scale clinical application of Treg; nevertheless, the concept of CAR (chimeric antigen receptor)-Treg has emerged as a potential resolution to the problem. Recently, two CAR-T therapies, tisagenlecleucel and axicabtagene ciloleucel, were approved by the US FDA for the treatment of refractory or recurrent acute lymhoblastic leukemia. This approval could serve as a guideline for the production protocols for other genetically engineered T cells for clinical use as well. The phase I and II clinical trials of these agents has demonstrated that genetically engineered and antigen-targeting T cells are safe and efficacious in humans. In conclusion, both the promising results of Treg cell therapy from the clinical studies and the recent FDA approval of CAR-T therapies are paving the way for CAR-Treg therapy in clinical use.]
(†04522) 서울 특별시 중구 남대문로 113 DB다동빌딩 5층
TEL : 02-737-8970 (기획운영팀)
Copyright (c)KONIBP All Right Reserved.
Copyright (c)KONIBP All Right Reserved.
2sisstore
